Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Edward R Scheffer Cliff, Penelope Lafeuille, Sheila Diamond, Jacob Aptekar, David A Russler-Germain, Kai Rejeski, Aaron S Kesselheim

Blood (2024) 144 (Supplement 1): 2077.

https://doi.org/10.1182/blood-2024-203979

Published: 2024

Journal Articles

Phosphorus Disruption Is Associated with the Incidence and Severity of Neurotoxicity Symptoms in CD19-Targeted CAR-T Cell Therapy: A Pooled Clinical Trial Analysis

Penelope Lafeuille, Sheila Diamond, Alexandru Socolov, Jacob Aptekar, Theodore Nowicki

Blood (2023) 142 (Supplement 1): 3626.

https://doi.org/10.1182/blood-2023-182138

Published: 2023

Journal Articles

Machine Learning-Based Decision Tree for Identifying and Grading Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Based on Neurological Adverse Events in Patients Treated with CD19 CAR-T

Alexandru Socolov, Penelope Lafeuille, Sheila Diamond, Eric Yang, Francesco Maura, Jacob Aptekar, Esther Nie

Blood (2023) 142 (Supplement 1): 5018.

https://doi.org/10.1182/blood-2023-182147

Published: 2023

Journal Articles

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Kayleen Ports, Rahul Jain, Sheila Diamond, Jacob Aptekar, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 6933.

https://doi.org/10.1182/blood-2023-181968

Published: 2023

Journal Articles

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease

Sheila K Pierson, MS, Laura Katz, MA, Christopher Sheild Nabel, MD PhD, Jason R Ruth, PhD, Sheila Diamond, MS, CGC, Hrishikesh Karvir, PhD, Fanyi Zhang, MS, Manjula P Reddy, MS, MSc, Mary Guilfoyle, MS, Craig Tendler, MD, Frits van Rhee, MD PhD, Philip Beineke, MS, Ana B Oromendia, PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2019) 134 (Supplement_1): 3599.

https://doi.org/10.1182/blood-2019-128284

Published: 2019

NARROW

Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Phosphorus Disruption Is Associated with the Incidence and Severity of Neurotoxicity Symptoms in CD19-Targeted CAR-T Cell Therapy: A Pooled Clinical Trial Analysis

Machine Learning-Based Decision Tree for Identifying and Grading Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Based on Neurological Adverse Events in Patients Treated with CD19 CAR-T

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease

Email alerts

ASH Publications

American Society of Hematology

Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Phosphorus Disruption Is Associated with the Incidence and Severity of Neurotoxicity Symptoms in CD19-Targeted CAR-T Cell Therapy: A Pooled Clinical Trial Analysis

Machine Learning-Based Decision Tree for Identifying and Grading Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Based on Neurological Adverse Events in Patients Treated with CD19 CAR-T

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only